Rare Cannabinoid Company Announces Autism Summit Sponsorship, Donation of CBDV a… – Press Release

[ad_1]

HONOLULU, March 2, 2022 /PRNewswire-PRWeb/ —  Rare Cannabinoid Company, a leading CBD and hemp cannabinoid company in the United States, has announced its support for the Autism Summit this April in the form of sponsorship and donation of CBD and CBDV oil products.

“One in 44 American children has been identified to have autism spectrum disorder,” said company co-founder Jennifer Carlile, citing a recent CDC report. “Autism affects so many people; the expert speakers at this free virtual event can educate and help in so many ways,” she said.

People with autism have different ways of thinking, communicating, understanding, being, and feeling. This spectrum of differences can make it more difficult for them to communicate and interact socially with others. Autistic people may also exhibit repetitive behaviors, agitation, irritability, and suffer from sleep deficits.

A number of recent studies on CBD for autism have shown positive results on symptoms. CBD oil is well known for promoting calm, balance, and stress resilience. Meanwhile, a less-known cannabinoid, CBDV (cannabidivarin), is also making headlines for research into CBDV and autism.

What is CBDV? Like CBD, CBDV is extracted from hemp and is not intoxicating, which means that it doesn’t get people high. CBDV benefits include social, behavioral, and memory support. Other potential CBDV effects have been documented in animal and human research on seizures, autism and Rett syndrome (which also falls under the autism umbrella).

This 2019 rodent study on CBDV and autism reports “the data provide preclinical evidence in support of the ability of CBDV to ameliorate behavioral abnormalities resembling core and associated symptoms of ASD.”

Several other studies on CBDV and autism look at how CBDV may normalize brain function and affect brain excitation and inhibition. Rodent studies on Rett syndrome (a form of autism) found CBDV improved sociability, memory, cognitive, neurological, and motor…

[ad_2]